Day: September 24, 2021
New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallow
Evrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwide
Further presentations included data from studies supporting the efficacy, safety, and durability of gene therapy, SRP-9001, in the treatment of Duchenne muscular dystrophy (DMD)Basel, 24 September 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic...
AKWEL: NET EARNINGS OF €38 M IN H1 2021
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Thursday 23 September 2021
NET EARNINGS OF €38 M IN THE H1 OF 2021
AKWEL (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid management and mechanisms, published its 2021 half-yearly results.Consolidated data – in € millions
30.06.2021
30.06.2020
Var. in %Revenue
487.6
387.0
+26.0%EBITDA
64.7
60.0
+7.9%Current operating income
50.0
24.3
+105.8%Current operating margin
10.3%
6.3%
+4.0 ptsOperating income
50.7
25.3
+100.9%Financial income
(0.6)
(1.0)
-36.8%Net result (group share)
38.0
20.2
+88.1%Net margin
7.8%
5.2%
+2.6 ptsIn the first half of 2021, AKWEL recorded consolidated revenue of €487.6 m, up 26.0% on 2020 and 33.7% at a constant scope and exchange rates, but it is still down nearly 14% compared to the same period of 2019....
Questerre files application for carbon storage reservoir test
Written by Customer Service on . Posted in Public Companies.
THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS
CALGARY, Alberta, Sept. 24, 2021 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) (TSX,OSE:QEC) reported it has filed an application with the Ministry of Energy and Natural Resource in Quebec to test a reservoir for carbon storage potential.
The operation will consist primarily of an injectivity test to gather data on both the safe rate of injection and storage potential. The Company identified the storage formation earlier this year after studying its proprietary seismic and well data. The Company holds the exclusive right to explore for storage reservoirs over one million acres in Quebec. Plans are underway for a 2-D and 3-D seismic survey over areas...
Dentsply Sirona announces a comprehensive restage of its Implant business
Written by Customer Service on . Posted in Public Companies.
With a digital base, historical product strength and signature workflows supported by ongoing education and training, Dentsply Sirona is launching DS Implants, harmonizing successful brands like Simplant, OSSIX, Atlantis and MIS.
Three completely connected, seamless signature workflows will take full advantage of digital dentistry for excellent outcomes and patient satisfaction.
DS Implants presents DS PrimeTaper, a self-tapping implant with a tapered design that can be inserted safely and easily with a unique double thread, enabling long-term bone stability.CHARLOTTE, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) introduces a comprehensive restage of its Implants business, including three signature workflows to provide dental professionals with a completely new way of practicing...
Immuron Director resignation
Written by Customer Service on . Posted in Public Companies.
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.
Mr Anastasiou joined the Board in May 2015 after becoming a major shareholder in 2013 and was appointed Vice Executive Chairman in August 2015 to assist US market development opportunities and supporting key programs at Immuron.
Mr Anastasiou commented that “Small companies rarely get an opportunity to acquire a transformative asset of national significance. Our shareholders have lost a chance to contribute to the advancement of very safe Covid vaccine. As a result, I have decided to step down despite my confidence...